MINNEAPOLIS, Minn.—Walman Optical announced it has added Avulux Migraine and Light Sensitivity Lenses to its portfolio, which the company stated will provide a groundbreaking solution for individuals suffering from migraine and light sensitivity. Avulux lenses are the world’s only clinically proven lens that blocks the harmful light wavelengths linked to migraine attacks, the announcement said. “We are thrilled to offer the Avulux lenses to our customers,” said Glen Funk, vice president of Walman Optical. “Our commitment is to provide innovative solutions that enrich the lives of patients through better vision. Avulux lenses are a game-changer for those affected by light sensitivity and migraine, and we believe this addition will make a significant impact.”

By partnering with Avulux authorized Labs, like Walman Optical, the company said eyecare professionals can enjoy a streamlined supply chain, exclusive bulk and wholesale discounts, and special incentives. ECPs will also receive comprehensive information and promotional materials to seamlessly integrate Avulux lenses into their practices. 

“We value Walman Optical’s partnership because, like us, they are committed to helping independent ECPs build practice growth and deliver an exceptional patient experience,” said Dr. Charles Posternack, president and CEO of Avulux. “Walman Optical believes in offering the latest in advanced technology, combined with superior customer service and continuing education, and we welcome them to our growing roster of labs across the country.”